Faxitron Bioptics has signed an agreement with Health Beacons to distribute the company's LOCalizer radiofrequency identification (RFID) breast lesion localization system.
LOCalizer is pending clearance from the U.S. Food and Drug Administration (FDA). It marks the lesion with a miniature RFID tag that guides the surgeon via a mobile handheld reader. Each tag has a unique identification number and can be implanted in the breast up to 30 days before surgery.
LOCalizer also features an attachable sterile single-use surgical probe, an integrated LED screen, and an audible tone that guides surgeons during procedures, Faxitron Bioptics said.
